Pei-Chia Su, Ching-Yu Chen, Min-Hua Yu, I-Ying Kuo, Pei-Shan Yang, Ching-Hsuan Hsu, Ya-Chin Hou, Hsin-Ta Hsieh, Chih-Peng Chang, Yan-Shen Shan, Yi-Ching Wang*. 2024. Fully human chitinase-3 like-1 monoclonal antibody inhibits tumor growth, fibrosis, angiogenesis, and immune cell remodeling in lung, pancreatic, and colorectal cancers. Biomed Pharmacother. May 30:176:116825 (IF 6.9, 21/189 in "MEDICINE, RESEARCH & EXPERIMENTAL")

Sheng-Kai Hsu, Chon-Kit Chou, I-Ling Lin, Wen-Tsan Chang, I-Ying Kuo* & Chien-Chih Chiu*. 2024. Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion. Cell Commun Signal. May 7; 22, 259 (IF 8.4, 34/191 in "CELL BIOLOGY")

Wan‑Ting Kuo, I‑Ying Kuo, Hung‑Chia Hsieh, Ssu‑Ting Wu, Wu‑Chou Su and Yi‑Ching Wang*. 2024. Rab37 mediates trafficking and membrane presentation of PD‑1 to sustain T cell exhaustion in lung cancer. Journal of Biomedical Science. Feb 7; 31(1):20. (IF 12.771, 24/194 in "CELL BIOLOGY")

Shaifali Singh, Nai Yang Yeat, Ya-Ting Wang, Shu-Yu Lin, I-Ying Kuo, Kuen-Phon Wu, Won-Jing Wang, Wen-Ching Wang, Wu-Chou Su, Yi-Ching Wang & Ruey-Hwa Chen*. 2023. PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target. Cell Death & Disease. Oct; 14:671. (IF 9.0, 31/191 in "CELL BIOLOGY")

Chang WL, Hsieh CH, Kuo I-Ying, Lin CH, Huang YL, Wang YC*. 2023. Nutlin-3 acts as a DNA methyltransferase inhibitor to sensitize esophageal cancer to chemoradiation. Mol Carcinog. Feb;62(2):277-287. (IF 5.139, 89/254 in "ONCOLOGY")

Hsieh CH, Kuan WH, Chang WL, Kuo I-Ying, Liu H, Shieh DB, Liu H, Tan B, Wang YC*. 2022. Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma, Journal of Biomedical Science. 30;29(1):90. (IF 12.771, 24/194 in "CELL BIOLOGY")

I-Ying Kuo, Chih‑Hsiung Hsieh, Wan‑Ting Kuo, Chih‑Peng Chang, Yi‑Ching Wang* 2022. Recent advances in conventional and unconventional vesicular secretion pathways in the tumor microenvironment, Journal of Biomedical Science. 29:1-56 Review (IF 12.771, 24/194 in "CELL BIOLOGY"); First author.

Yang PS, Yu MH, Hou YC, Chang CP, Lin SC, I-Ying Kuo, Su PC, Cheng HC, Su WC, Shan YS, Wang YC. 2022. Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy. Theranostics. 12(1): 340-361. (IF 11.556, 9/140 in “Medicine, Research & Experimental”)

I-Ying Kuo, Danping Liu, Wu-Wei Lai, Yi-Ching Wang; and Y. Peng Loh. 2021. Carboxypeptidase E mRNA: overexpression predicts recurrence and death in lung adenocarcinoma cancer patients. Cancer Biomarkers, DOI:10.3233/cbm-210206. (IF 4.388, 112/242 in “Oncology”); First author.

I-Ying Kuo, Yang YE, Yang PS, Tsai YJ, Tzeng HT, Cheng HC, Kuo WT, Su WC, Chang CP*, Wang YC*. 2021. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics, 11(14): 7029-7044. (cover article) (IF 11.556, 9/140 in “Medicine, Research & Experimental”); First author.

Wang WR, Chen NT, Hsu NY, I-Ying Kuo, Chang HW, Wang JY, Su HJ*. 2021. Associations among phthalate exposure, DNA methylation of TSLP, and childhood allergy. Clin Epigenetics, 13(1):76. (IF 6.551, 53/242 in “ONCOLOGY”, 21/175 in “Genetics & Heredity”)

Lin CC, I-Ying Kuo, Wu LT, Kuan WH, Liao SY, Jen J, Yang YE, Tang CW, Chen YR, Wang YC* 2020. Kras/YY1/ZNF322A/Shh transcriptional axis enhances neo-angiogenesis to promote lung cancer progression. Theranostics, 10(22): 10001-10015. (IF 11.556, 9/140 in “Medicine, Research & Experimental”)

Ding LY, Hou YC, I-Ying Kuo, Hsu TY, Tsai TC, Chang HW, Hsu WY, Tsao CC, Tian CC, Wang PS, Wang HC, Lee CT, Wang YC, Lin SH, Hughes MW, Chuang WJ, Lu PJ, Shan YS, Huang PH. 2020. Epigenetic silencing of AATK in acinar to ductal metaplasia in murine model of pancreatic cancer. Clin Epigenetics, 12, 87. (IF 6.551, 53/242 in “ONCOLOGY”, 21/175 in “Genetics & Heredity”)

Liao SY, I-Ying Kuo, Chen YT, Liao PC, Liu YF, Wu HY, Lai WW, Wang YC*. 2019. AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression. Oncogene. 38(41): 6723-6736 (IF 9.867, 30/242 in “Oncology”)

I-Ying Kuo, Huang YL, Lin CY, Lin CH, Chang WL, Lai WW, Wang YC*. 2019. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes. J Biomed Sci. 2019 Feb 18;26(1): 20. doi: 10.1186/s12929-019-0510-4. (IF 8.410, 15/140 in “Medicine, Research & Experimental”); First author.

Cho SH#, I-Ying Kuo#, Lu PJ, Tzeng HT, Lai WW, Su WC, Wang YC*. 2018. Rab37 mediates exocytosis of secreted frizzled-related protein 1 to inhibit Wnt signaling and thus suppress lung cancer stemness. Cell Death and Disease. 29;9(9):868. (IF 8.469, 37/195 in “Cell Biology”); co- first author.

Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao Tsai, Chun-Hsien Wu, Li-Wen Hsu, Li-Yu Chen, Chao-Pin Kung, Yu-Fan Cheng, Shigeru Goto, Yu-Wei Chou, Chao-Long Chen, Chih-Che Lin, and Kuang-Den Chen*. 2017. Factor VII- Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma. Molecular Therapy: Nucleic Acids, 15; 9: 274–283. (IF 8.886, 13/140 in “medicine, research, and experimental”).

W.-L. Chang, W.-W. Lai, I-Ying Kuo, C.-Y. Lin, P.-J. Lu, B.-S. Sheu*, Y.-C Wang*. 2017. A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma. J. of Gastroenterol. 52(6):705-714 (IF 7.527, 17/92 in “Gastroenterology & Hepatology”)

I-Ying Kuo, J. Jen, L.-H. Hsu, H.-S. Hsu, W.-W. Lai*, Y.-C. Wang*. 2016. A prognostic predictor panel with DNA methylation biomarkers for early-stage lung adenocarcinoma in Asian and Caucasian populations. J. of Biomed. Sci. 23(1):58 (IF 8.410, 15/140 in “Medicine, Research & Experimental”); First author.

K-D Chen, K-T Huang, M-C Tsai, C-H Wu, I-Ying Kuo, L-Y Chen, T-H Hu, C-L Chen and C-C Lin*. 2016. Coagulation factor VII and malignant progression of hepatocellular carcinoma. Cell Death Dis., 7:e2110. (IF 4.53, 12/298 in “Biochemistry & Molecular biology”).

M-C Tsai, K-D Chen, C-C Wang, K-T Huang, C-H Wu, I-Ying Kuo, L-Y Chen, T-H Hu, S Goto, T Nakano, A Dorling, JH McVey, C-L Chen and C-C Lin*. 2015. Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling. Cell Death Discov. Nov 30;1:15051

Ruo-Chia Tseng, Jia-Ming Chang, Jeng-Hung Chen, Way-Ren Huang, Yen-An Tang, I-Ying Kuo, Jing-Jou Yan, Wu-Wei Lai, Yi-Ching Wang*. 2015. Deregulation of SLIT2-mediated cdc42 activity is associated with esophageal cancer metastasis and poor prognosis. J Thorac Oncol. Jan;10(1):189-98. (IF 5.282, 7/58 in "RESPIRATORY SYSTEM").

Chung-Han Tsai, Hung-Chi Cheng, Yu-Shiuan Wang, Pinpin Lin, Jayu Jen, I-Ying Kuo, Ying-Hua Chang, Pao-Chi Liao, Ruey-Hwa Chen, Wei-Chien Yuan, Han-Shui Hsu, Muh-Hwa Yang, Ming-Ta Hsu, Chu-Yi Wu* & Yi-Ching Wang*. 2014. Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumour metastasis. Nature Communications. vol. 5: 4804. (IF 10.742, 3/55 in "MULTIDISCIPLINARY SCIENCES").

Chun-Pei Cheng#, I-Ying Kuo#, Hakan Alakus, Kelly A. Frazer, Olivier Harismendy, Yi-Ching Wang,* and Vincent S. Tseng*. 2014. Network-based analysis identifies epigenetic biomarkers of esophageal squamous cell carcinoma progression. Bioinformatics. Nov 1;30(21):3054-61. (IF4.621, 18/165 in "BIOTECHNOLOGY & APPLIED MICROBIOLOGY" ); co- first author.

I-Ying Kuo, Jia-Ming Chang, Shih-Sheng Jiang, Chung-Hsin Chen, I-Shou Chang, Bor-Shyang Sheu, Pei-Jung Lu, Wei-Lun Chang, Wu-Wei Lai, Yi-Ching Wang*. 2014. Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients. Int J Med Sci. 30;11(8):779-87. (IF 1.552, 65/156 in "MEDICINE, GENERAL & INTERNAL"); First author.

I-Ying Kuo, Ching-Chi Wu, Jia-Ming Chang, Yu-Lin Huang, Chien-Hsun Lin, Jing-Jou Yan, Bor-Shyang Sheu, Pei-Jung Lu, Wei-Lun Chang, Wu-Wei Lai, Yi-Ching Wang*. 2013. Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression. Int J Cancer. 1;135(3):563-73. (IF 6.198, 23/197 in "ONCOLOGY"); First author.